Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
1.645
+0.035 (2.17%)
At close: Nov 13, 2026, 4:00 PM EST
1.688
+0.043 (2.63%)
After-hours: Nov 13, 2026, 7:56 PM EST
Altimmune Revenue
Altimmune had revenue of $26.00K in the twelve months ending September 30, 2026, up 30.00% year-over-year. In the year 2025, Altimmune had annual revenue of $41.00K with 105.00% growth. That makes Altimmune the 46,886th largest company in the world by revenue and 7,048th in the United States.
Revenue (ttm)
$26.00K
Revenue Growth
+30.00%
P/S Ratio
12,311.52
Revenue / Employee
$456
Employees
57
Market Cap
320.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.00K | 21.00K | 105.00% |
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | - |
| Dec 31, 2022 | -68.00K | -4.48M | - |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | 10.33M | -407.15K | -3.79% |
| Dec 31, 2017 | 10.74M | 7.50M | 231.82% |
| Dec 31, 2016 | 3.24M | -7.40M | -69.59% |
| Dec 31, 2015 | 10.64M | 450.46K | 4.42% |
| Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
| Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
| Dec 31, 2012 | 25.18M | 909.61K | 3.75% |
| Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
| Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
| Dec 31, 2009 | 27.55M | -5.36M | -16.29% |
| Dec 31, 2008 | 32.91M | 18.27M | 124.75% |
| Dec 31, 2007 | 14.64M | 12.98M | 780.39% |
| Dec 31, 2006 | 1.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alector | 173.47M |
| Autolus Therapeutics | 137.43M |
| ARS Pharmaceuticals | 122.14M |
| Fennec Pharmaceuticals | 59.22M |
| Editas Medicine | 49.83M |
| Precision BioSciences | 45.04M |
| C4 Therapeutics | 32.28M |
| Prelude Therapeutics | 22.42M |
ALT News
- 20 hours ago - Altimmune price target lowered to $11 from $13 at B. Riley - TheFly
- 1 day ago - Altimmune Earnings Call Transcript: Q3 2026 - Transcripts
- 1 day ago - Altimmune Earnings release: Q3 2026 - Filings
- 1 day ago - Altimmune Quarterly report: Q3 2026 - Filings
- 1 day ago - Altimmune reports Q3 EPS (15c), consensus (14c) - TheFly
- 1 day ago - Altimmune Announces Third Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 1 day ago - Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 4 days ago - Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder - GlobeNewsWire